MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phas…
Biotechnology
CH, Zug [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared MoonLake Immunotherapeutics (MLTX) to it's peer group, including competitors as well as it's industry.
All monetary values in mil. except volume - volume is in thousands.
Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biotechnology Average | - - | - - | - - | 37,157.53 | 13,308.38 | 703.73 | 324.72 | -1,050.36 | 0.00 | 25.0820 | 44.73 | -0.8104 | -20.3393 | -0.08 | -0.07 | 6.0022 | - - | ||
Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 37.1953 | - - | ||
Minimum | - - | - - | - - | 0.00 | 0.00 | -6,783.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -57.22 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
Nuvalent, Inc. NUVL | 92.73 | 1.56 1.71% | 389 vs. 533 | 6,588.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 71.00 | ||
Structure Therapeutics Inc. GPCR | 30.10 | -2.61 -7.98% | 821 vs. 712 | 1,723.00 | 0.00 | -26.00 | -34.00 | -232.00 | -0.5600 | -18.2892 | 0.0000 | 0.0000 | 0.0000 | -0.0606 | -0.0569 | 18.5046 | 57.00 | ||
Akero Therapeutics, Inc. AKRO | 31.20 | 0.57 1.84% | 522 vs. 551 | 2,177.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
Arcellx, Inc. ACLX | 87.22 | 0.00 0.00% | 324 vs. 537 | 4,716.00 | 39.00 | -7.00 | -38.00 | -396.00 | -0.1400 | -122.7330 | 0.0000 | 0.9790 | -0.1834 | -0.0145 | -0.0092 | 5.3496 | 54.00 | ||
MoonLake Immunotherapeutics MLTX | 51.86 | 2.04 4.09% | 247 vs. 301 | 3,270.00 | 0.00 | -13.00 | -15.00 | -130.00 | -0.2200 | -55.6575 | 0.0000 | 0.0000 | 0.0000 | -0.0252 | -0.0242 | 61.5621 | 63.00 | ||
Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 |
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.